Cerus Corporation (NASDAQ: CERS) has announced revenue of $37.8 million in Q2 2021, reflecting a 41% YoY increase. This was the highest quarterly total revenue in the company’s history.
Cerus reports record Q2 revenue
The company’s CEO and President William ‘Obi’ Greenman said, “The second quarter of 2021 was exceptional for Cerus on numerous fronts. Our record quarterly product revenue of $31.5 million exceeded our expectations and was led by U.S. platelet adoption. This strong momentum gives us confidence in delivering significant top-line growth over the balance of the year, and we are raising our full year product revenue guidance accordingly.”
During the quarter, the company reported record product revenue of $31.5 million attributed to growing INTERCEPT platelet products to demand in the US following increased demand across the nation from blood centers. In addition, government contract revenue was $6.3 million. It comprised funding related to R&D efforts for the INTERCEPT Blood System for Red Cells and sponsored activities associated with next-gen pathogen reduction tech development for whole blood treatment.
Cerus expects 2021 product revenue to be between $118 million and $122 million based on string 1H 2021 revenue and 2H 2021 expectations relative to the earlier revenue guidance of $110 to $114 million.
Cerus submitted a PMA supplement
The company submitted a PMA supplement to the FDA for the seven-day INTERCEPT platelet storage during the quarter. Equally, Cerus announced a collaboration with LifeSouth Community Blood Centres to produce the INTERCEPT Fibrinogen Complex.
Greenman added, “As planned, we made two important regulatory submissions, with our PMA supplement to the FDA for 7-day storage of INTERCEPT platelets, as well as the fourth and final module of our CE Mark submission for INTERCEPT red blood cells. In addition, for our therapeutics business, we have signed initial customer contracts with hospitals who plan to begin using INTERCEPT Fibrinogen Complex in the second half of 2021, expanded our initial reach into the state of Florida through our collaboration with LifeSouth and received the NTAP from CMS.”
